A screening method was established to detect inhibitors of the biosynthetic pathways of aromatic amino acids and para-aminobenzoic acid, the precursor of folic acid, using an agar A successful search for novel antibacterial metabolites has to meet three criteria, first, a specific target which is essential for the metabolism of a bacterium and not yet provided with an known inhibitor. Second, a set of taxonomically characterized and dereplicated microorganisms as producers of secondary metabolites, and last but not least a lucky but experienced hand for strain isolation and cultivation. We have chosen the shikimate pathway as an essential target of bacterial metabolism, with special consideration of the biosynthesis of aromatic amino acids and para-aminobenzoic (pAba) acid derived from the keymetabolite chorismate. Only a few antimetabolites are known as inhibitors of aromatic amino acids, such as L-2,5-dihydrophenylalanine2), an antagonist of phenlyalanine, and glyphosate that inhibits 3-enolpyruvylshikimate-3-phosphate synthase3,4). To our knowledge, no natural product inhibitor of pAba biosynthesis has been described in the literature. This pathway, which is catalyzed by two enzymes, 4-amino-4-deoxychorismic acid (ADC) synthase and ADC lyase, seems to be of considerable interest for the development of novel antibiotics since it is directly linked to folic acid biosynthesis, which is established in plants, fungi, prokaryotes and parasites of the apicomplexa group (Plasmodium, Toxoplasma) but not in vertebrates.
(Received for publication January 29, 2004) A screening method was established to detect inhibitors of the biosynthetic pathways of aromatic amino acids and para-aminobenzoic acid, the precursor of folic acid, using an agar plate diffusion assay modified as an antagonism test. By this screening method, a family of three novel polycyclic polyketides named as abyssomicins was isolated from a marine strain of Verrucosispora.
The main component abyssomicin C inhibits the pathway between chorismate and para-aminobenzoic acid and is strongly active against Gram-positive bacteria, including multi-resistant clinical isolates of Staphylococcus aureus.
A successful search for novel antibacterial metabolites has to meet three criteria, first, a specific target which is essential for the metabolism of a bacterium and not yet provided with an known inhibitor. Second, a set of taxonomically characterized and dereplicated microorganisms as producers of secondary metabolites, and last but not least a lucky but experienced hand for strain isolation and cultivation. We have chosen the shikimate pathway as an essential target of bacterial metabolism, with special consideration of the biosynthesis of aromatic amino acids and para-aminobenzoic (pAba) acid derived from the keymetabolite chorismate. Only a few antimetabolites are known as inhibitors of aromatic amino acids, such as L-2,5-dihydrophenylalanine2), an antagonist of phenlyalanine, and glyphosate that inhibits 3-enolpyruvylshikimate-3-phosphate synthase3,4). To our knowledge, no natural product inhibitor of pAba biosynthesis has been described in the literature. This pathway, which is catalyzed by two enzymes, 4-amino-4-deoxychorismic acid (ADC) synthase and ADC lyase, seems to be of considerable interest for the development of novel antibiotics since it is directly linked to folic acid biosynthesis, which is established in plants, fungi, prokaryotes and parasites of the apicomplexa group (Plasmodium, Toxoplasma) but not in vertebrates.
As suitable producers of bioactive metabolites we screened within the order Actinomycetales terrestrial and marine members of the families Streptomycetaceae and Micromonosporaceae and rare actinomycete genera. A total of 930 extracts derived from 201 actinomycetes were subjected to the screening. Among them, only AB-18-032, an extract from a marine isolate from a sediment collected from the Sea of Japan, was found to exhibit activity against species. In a pre-screen using an agar plate diffusion assay with Bacillus subtilis as test organism, only extracts from microorganisms were of interest which showed a selective antibacterial activity against the test organism grown on a minimal medium, and no activity was observed when grown on a complex medium.
In the second stage of testing these previously active extracts were submitted to a more detailed antagonism assay that allowed us to distinguish between the inhibition of the discrete biosynthetic pathways of Trp, Tyr/Phe and to pAba branching off from chorismate. Similarly, the inhibition of the biosynthetic pathway prior to chorismate was tested. As a consequence, four agar plates in which B.
subtilis was seeded in a minimal medium were necessary in the antagonism test for the evaluation of each extract. The filter paper strip which was placed on the agar plate across the antibiotic containing strip was soaked with solutions of 
Taxonomy of the Producing Strain
Strain AB-18-032 was assigned to the family Micromonosporaceae on the basis of its morphological and chemotaxonomic properties. The organism forms a well developed, branched, red coloured substrate mycelium which carries single spores which have a warty ornamentation (Fig. 2) . Aerial hyphae and sporangia were not found. The peptidoglycan is rich in mesodiaminopimelic acid and contains N-glycolated muramic acid. Mannose and xylose are the major sugars and hexahydrogenated menaquinones with nine isoprene units the predominant isoprenologue.
A nearly complete 16S rRNA gene sequence (1440 nucleotides) of strain AB-18-032 was compared with corresponding sequences of representatives of the suborder Micromonosporineae (Fig. 3) . It is evident from the Figure that the tested strain is most closely related to the type strain of Verrucosispora gifhornensis16), the sole representative of the genus Verrucosispora. It is evident from Table 1 that the two strains can be distinguished using a combination of phenotypic properties. The antimicrobial spectra of abyssomicins B, C and D were examined by an agar plate diffusion assay. Only abyssomicin C was antibiotically active and showed a strong inhibitory activity against Gram-positive bacteria (Table 2) . Gram-negative bacteria and fungi were not sensitive to abyssomicin C. As could be expected, the inhibitory activity of abyssomicin C was significantly stronger when the test organisms were cultivated in minimal media, as shown for the representative test 
